FDA fails to approve cholesterol drug for kidney disease Reuters By Anna Yukhananov | WASHINGTON (Reuters) - US health regulators amended the prescribing label for Merck & Co's cholesterol-lowering drug Vytorin to show it prevents heart problems in patients with chronic kidney disease, but stopped short of approving ... Merck Cholesterol Drug Helps Heart, FDA Label Says FDA Turns Down Expanded Use of Merck's Vytorin and Zetia New FDA Approved Labeling For VYTORIN® (Ezetimibe/Simvastatin) Includes ... |
